API
< Back to all clusters
[BUSINESS] · Armenia · 2 sources

started · updated

Agenus Inc. receives marketing authorizations in Armenia

Agenus Inc. has received conditional marketing authorizations from Armenia's Ministry of Health for its immuno-oncology combination, Botvymo (botensilimab) and Evamplix (balstilimab). The approvals, effective October 2, are for adults with previously treated microsatellite-stable metastatic colorectal cancer without active liver metastases.

The Armenian authorizations are valid for one year and are renewable based on annual clinical updates. They apply to treatment within Armenia, including patients traveling there under the care of Armenian oncologists.

Regarding clinical development, Agenus reported that first patient enrollment for the Phase 3 ROBBIN trial remains on track for the first quarter of 2027. The company stated its current financing supports operations through the third quarter of 2027. As of early November, Agenus reported US$86.9 million in cash, cash equivalents, and short-term investments, alongside US$17 million in pre-commercial product revenue from global patient-access programs through September.

Entities

Agenus Inc. · Armenia · Ministry of Health of Armenia